eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Forest Laboratories UK Limited

Riverbridge House, Anchor Boulevard, Crossways Business Park, Dartford, Kent, DA2 6SL
Telephone: +44 (0)1322 421 800
Fax: +44 (0)1322 291 306
WWW: http://www.forestlabs.com
Medical Information e-mail: medinfo@forest-labs.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 17/02/2011
SPC Exorex Lotion 5% v/w Cutaneous Emulsion


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Exorex Lotion 5% v/w Cutaneous Emulsion


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

The active ingredient is coal tar solution 5% v/w.

Excipients:

 

Methyl hydroxybenzoate (E218)

0.10% w/w

Propyl hydroxybenzoate (E216)

0.05% w/w

Hydrogenated polyoxyl castor oil

0.45% w/w

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Cutaneous emulsion

A smooth mustard coloured emulsion.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Exorex is for the treatment of psoriasis of the skin and scalp.


Go to top of the page
4.2 Posology and method of administration

Adults and children over 12 years of age:

Ensure that the lesions are clean. Apply a thin layer of Exorex two or three times per day to the affected areas. Massage gently and leave to dry.

For young children under 12 years of age and the elderly:

The emulsion may be diluted by mixing with a few drops of freshly boiled and cooled water in the palm of the hand.


Go to top of the page
4.3 Contraindications

Do not use if sensitive to any of the ingredients.

Presence of folliculitis and acne vulgaris.

Exorex should not be used on patients who have disease characterised by photosensitivity such as lupus erythematosus or allergy to sunlight.

Exorex should not be applied to inflamed or broken skin (open exuding wounds or infection of the skin).


Go to top of the page
4.4 Special warnings and precautions for use

Coal tar may cause skin irritation. If irritation occurs, the treatment should be reviewed and discontinued if necessary.

Coal tar enhances photosensitivity of the skin, and exposure to direct sunlight after application of Exorex should be avoided.

Use with care near the eyes and mucous membranes. If any emulsion should accidentally enter the eye, flush with normal saline solution or water.

Do not apply to genital and rectal areas.

Apply with caution to the face.

Hydrogenated polyoxyl castor oil may cause skin reactions. Methyl and propyl hydroxybenzoates may cause allergic reactions that might be delayed.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known


Go to top of the page
4.6 Pregnancy and lactation

There is inadequate evidence of safety in pregnant and lactating women but coal tar preparations have been in use for many years without apparent ill-consequence and no harmful effects on the health of the child is anticipated with the proper use of this product. However it is recommended that the use of coal tar in pregnancy and lactation be restricted to intermittent use, in a low concentration on a relatively small percentage of body surface and that use during the first trimester be avoided.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known


Go to top of the page
4.8 Undesirable effects

Skin and subcutaneous tissue disorders:

Skin irritation, photosensitivity of the skin. In addition coal tar may cause acne-like eruptions of the skin.

An increased risk of skin cancer in psoriatic patients treated with a combination of coal tar and UVB radiation has been reported. However epidemiological studies of patients treated with coal tar alone are inconclusive. The risk of toxicity should be taken into account when considering the suitability of this product for the patient (see also Section 5.3).


Go to top of the page
4.9 Overdose

There is no evidence that overdose of topical Exorex would be harmful other than possibly inducing a hypersensitivity to coal tar. Ingestion of Exorex may require gastric lavage depending on the quantity taken and should be treated symptomatically.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Exorex contains coal tar, an antipruritic and keratoplastic. It is used in eczema, psoriasis and other skin conditions. Tar acids have also been shown to have disinfectant properties. Exorex may be used alone, or as part of a more extensive treatment regimen.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

In animal studies coal tar has been shown to increase the incidence of epidermal carcinomas and self-limiting keratoacanthomas.

While the ingredients of coal tar have been shown to express genotoxic properties, epidemiological studies with patients have been shown to be inconclusive concerning the potential carcinogenic risks of coal tar products in human long term treatment. Nevertheless the possible risk of prolonged treatment should be taken into account when considering the usage of the product.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

dl-Alpha tocopherol

Vitamin F ethyl ester

Xanthan gum

Propyl hydroxybenzoate (E216)

Methyl hydroxybenzoate (E218)

Hydrogenated polyoxyl castor oil

Purified water


Go to top of the page
6.2 Incompatibilities

Not applicable


Go to top of the page
6.3 Shelf life

2 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

High density polyethylene bottle containing titanium dioxide.

Polypropylene green flip-top caps.

Pack sizes: 100 and 250ml

A professional sales pack of 30ml is also available.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

Shake the bottle before use.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Forest Tosara Limited

Baldoyle Industrial Estate

Grange Road

Dublin 13

Ireland


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 06166/0001


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

3 November 1999 / 23 May 2007


Go to top of the page
10. DATE OF REVISION OF THE TEXT

January 2011


Go to top of the page
11. LEGAL CATEGORY

GSL



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/7628/SPC/


Active Ingredients/Generics

 
   coal tar solution